A new study published in JAMA Internal Medicine reveals that the expedited reviews of new drugs that had been approved by the US Food and Drug Administration made use of fewer patients in their trials and some safety questions remained unanswered. The FDA is authorized to make new drugs available more quickly if they would be a significant therapeutic advancement and if they fulfill unmet therapeutic needs for serious illnesses, according to the study background.br ...
Read MoreYou have just read an article categorized health
titled Safety Questions Persist for Some Drugs Despite Expedited Approvals by FDA.
Written by:
editor - Thursday, October 31, 2013
There are currently no comments for "Safety Questions Persist for Some Drugs Despite Expedited Approvals by FDA"
Post a Comment